BridgeMD
New treatment option for Familial Mediterranean Fever
Official title is There an Effect of Adding Body Vibration to Intake of Vitamin D on Some Outcomes of Familial Mediterranean Fever
ClinicalTrials.gov ID: NCT07130305
What this study is testing
- What it's testing
- Familial mediterranean fever (FMF) is common in mediterranean region. this disorder is connected with deterioration in functional performance, fitness of cardiorespiration, muscle strength, and bone mass
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 13 to 17, women only
You may be able to join if
- FMF adolecent girls ages 13 -17 years forty patients
You likely can't join if
- cardiac problems renal problems liver problems diabetes brain problems
The study team makes the final eligibility decision.
Where it's taking place
- Giza, Dokki, Egypt
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling female, 13 years to 17 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Giza, Dokki, Egypt. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.